Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Keating

Showing results (581-590 of 1,289) with videos related to

Pageof 129
Sort By:
Leukemia & Lymphoma|June 1, 1996
Amsacrine and continuous-infusion high-dose cytosine arabinoside as induction therapy for patients with newly-diagnosed acute myelogenous leukemiaH M Ghaddar, S Pierce, H M Kantarjian, et al.
The Journal of Physiology|January 16, 2004
Opioid receptor stimulation suppresses the adrenal medulla hypoxic response in sheep by actions on Ca(2+) and K(+) channelsDamien J Keating, Grigori Y Rychkov, Michael B Adams, et al.
Cancer|March 1, 1990
Fatal pulmonary failure complicating high-dose cytosine arabinoside therapy in acute leukemiaB S Andersson, M A Luna, C Yee, et al.
Addiction Biology|January 7, 2016
Biochemical and genetic studies of Caucasian subjects with ethanol-induced flushing reactionR J Ward, J Mccradden, K Tipton, et al.
Cancer|July 1, 1989
Experience with vincristine, doxorubicin, and dexamethasone (VAD) chemotherapy in adults with refractory acute lymphocytic leukemiaH M Kantarjian, R S Walters, M J Keating, et al.
Cancer Treatment Reports|January 1, 1981
Prognostic factors in response to anthracyclinesK B McCredie, M J Keating, G P Bodey, et al.
Cancer|March 15, 1981
Chemoimmunotherapy of adult acute leukemiaK B McCredie, G P Bodey, E J Freireich, et al.
Leukemia|April 1, 1989
Prediction of survival during induction therapy in patients with newly diagnosed acute myeloblastic leukemiaE Estey, T L Smith, M J Keating, et al.
Leukemia Research|May 26, 2004
Telomerase activity is not a prognostic factor in chronic lymphocytic leukemiaSrdan Verstovsek, Francis J Giles, Susan O'Brien, et al.
Natural Immunity and Cell Growth Regulation|January 1, 1987
Augmentation of antileukemia lytic activity by OKT3 monoclonal antibody: synergism of OKT3 and interleukin-2E Lotzová, C A Savary, R B Herberman, et al.
Pageof 129

Showing results (581-590 of 1,289) with videos related to

Sort By:
Pageof 129
Leukemia & Lymphoma|June 1, 1996
Amsacrine and continuous-infusion high-dose cytosine arabinoside as induction therapy for patients with newly-diagnosed acute myelogenous leukemiaH M Ghaddar, S Pierce, H M Kantarjian, et al.
The Journal of Physiology|January 16, 2004
Opioid receptor stimulation suppresses the adrenal medulla hypoxic response in sheep by actions on Ca(2+) and K(+) channelsDamien J Keating, Grigori Y Rychkov, Michael B Adams, et al.
Cancer|March 1, 1990
Fatal pulmonary failure complicating high-dose cytosine arabinoside therapy in acute leukemiaB S Andersson, M A Luna, C Yee, et al.
Addiction Biology|January 7, 2016
Biochemical and genetic studies of Caucasian subjects with ethanol-induced flushing reactionR J Ward, J Mccradden, K Tipton, et al.
Cancer|July 1, 1989
Experience with vincristine, doxorubicin, and dexamethasone (VAD) chemotherapy in adults with refractory acute lymphocytic leukemiaH M Kantarjian, R S Walters, M J Keating, et al.
Cancer Treatment Reports|January 1, 1981
Prognostic factors in response to anthracyclinesK B McCredie, M J Keating, G P Bodey, et al.
Cancer|March 15, 1981
Chemoimmunotherapy of adult acute leukemiaK B McCredie, G P Bodey, E J Freireich, et al.
Leukemia|April 1, 1989
Prediction of survival during induction therapy in patients with newly diagnosed acute myeloblastic leukemiaE Estey, T L Smith, M J Keating, et al.
Leukemia Research|May 26, 2004
Telomerase activity is not a prognostic factor in chronic lymphocytic leukemiaSrdan Verstovsek, Francis J Giles, Susan O'Brien, et al.
Natural Immunity and Cell Growth Regulation|January 1, 1987
Augmentation of antileukemia lytic activity by OKT3 monoclonal antibody: synergism of OKT3 and interleukin-2E Lotzová, C A Savary, R B Herberman, et al.
Pageof 129